Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study

[1]  Jason C. Gallagher,et al.  Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  F. Cinetto,et al.  Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic , 2022, Frontiers in Immunology.

[3]  N. Gronich,et al.  Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  C. Agrati,et al.  Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway , 2022, Frontiers in Immunology.

[5]  C. Huff,et al.  Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients , 2022, Open forum infectious diseases.

[6]  M. Berhe,et al.  Effect on SARS-CoV-2 viral load using combination therapy with casirivimab/imdevimab and remdesivir , 2022, Proceedings.

[7]  Rui Qiao,et al.  Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages , 2022, Cell Host & Microbe.

[8]  A. Iwasaki,et al.  De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report , 2022, Nature Communications.

[9]  S. Becker,et al.  Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach , 2022, The Lancet Infectious Diseases.

[10]  J. Fernández-Niño,et al.  Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort , 2022, The Lancet Healthy Longevity.

[11]  A. Telenti,et al.  The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2 , 2022, bioRxiv.

[12]  M. Baniecki,et al.  Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.

[13]  M. Massari,et al.  Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study , 2022, BMJ.

[14]  G. Viglietto,et al.  Whole-genome analysis of SARS-CoV-2 in a 2020 infection cluster in a nursing home of Southern Italy , 2022, Infection, Genetics and Evolution.

[15]  S. Zeger,et al.  Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.

[16]  D. Fremont,et al.  An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies , 2022, Nature Medicine.

[17]  P. Maes,et al.  Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern , 2021, bioRxiv.

[18]  Benjamin Kye Jyn Tan,et al.  Efficacy of COVID-19 vaccines in immunocompromised patients: A systematic review and meta-analysis , 2021, medRxiv.

[19]  J. Skarbinski,et al.  Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients , 2021, The New England journal of medicine.

[20]  J. Butterton,et al.  Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients , 2021, The New England journal of medicine.

[21]  Y. Kreiss,et al.  Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection , 2021, medRxiv.

[22]  S. Schrag,et al.  Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data , 2021, The Lancet.

[23]  P. Pang,et al.  Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. , 2021, The New England journal of medicine.

[24]  J. Lennerstrand,et al.  Global Prevalence of Adaptive and Prolonged Infections’ Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein , 2021, Viruses.

[25]  John D. Davis,et al.  REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 , 2021, The New England journal of medicine.

[26]  Colin Simpson,et al.  COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study , 2021, The Lancet Respiratory Medicine.

[27]  M. López-Dosil,et al.  Incidence, clinical presentation, relapses and outcome of SARS-CoV-2 infection in patients treated with anti-CD20 monoclonal antibodies. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  D. Skovronsky,et al.  Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 , 2021, The New England journal of medicine.

[29]  O. Pybus,et al.  Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool , 2021, Virus evolution.

[30]  S. McCarthy,et al.  The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies , 2021, Cell.

[31]  C. Robertson,et al.  Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study , 2021, BMJ.

[32]  R. Walensky,et al.  CDC Interim Recommendations for Fully Vaccinated People: An Important First Step. , 2021, JAMA.

[33]  D. Ho,et al.  Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.

[34]  D. Skovronsky,et al.  Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[35]  Hong Luo,et al.  Spectrum and Clinical Characteristics of Symptomatic and Asymptomatic Coronavirus Disease 2019 (COVID-19) With and Without Pneumonia , 2020, Frontiers in Medicine.

[36]  OUP accepted manuscript , 2021, The Journal of Infectious Diseases.

[37]  F. Costanzo,et al.  Clinical characteristics and predictors of mortality associated with COVID-19 in elderly patients from a long-term care facility , 2020, Scientific Reports.

[38]  Gaurav D. Gaiha,et al.  Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host , 2020, The New England journal of medicine.

[39]  Zhènglì Shí,et al.  Characteristics of SARS-CoV-2 and COVID-19 , 2020, Nature Reviews Microbiology.

[40]  C. Rice,et al.  Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants , 2020, bioRxiv.

[41]  William J. Liu,et al.  A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.

[42]  Reem A Mustafa,et al.  Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  A. M. Leontovich,et al.  The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.

[44]  D. Fisher,et al.  Q&A: The novel coronavirus outbreak causing COVID-19 , 2020, BMC Medicine.

[45]  Lisa E. Gralinski,et al.  Return of the Coronavirus: 2019-nCoV , 2020, Viruses.

[46]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..